NCT02914366: Ambroxol as a Treatment for Parkinson's Disease Dementia
- State
- State not given
- Phase
- Phase 2
- People
- 55 taking part
- Started
- Nov 2015
- Primary completion
- Dec 2025
- Arms
- Ambroxol high dose (1050 mg)
- Results
- None posted
- Papers
- doi:10.1001/jamaneurol.2025.1687, doi:10.1186/s12883-019-1252-3
- 26 Sep 2016: Trial registered